---
layout: default
title: Ibuprofen
description: "Ibuprofen çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 7 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 84
evidence_level: L5
indication_count: 7
---

# Ibuprofen

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>7</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ibuprofenï¼šå¾è§£ç†±é®ç—›åˆ°ç½•è¦‹éª¨éª¼ç–¾ç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ibuprofen å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Ibuprofen åŸæœ¬ç”¨æ–¼è§£ç†±é®ç—›åŠæ²»ç™‚é—œç¯€ç‚ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**è‚¢ç«¯è‚¢ä¸­ç™¼è‚²ä¸è‰¯ (acromesomelic dysplasia)** ç­‰ç½•è¦‹éª¨éª¼ç–¾ç—…æœ‰æ•ˆï¼Œ
ä½†ç›®å‰**ç„¡è‡¨åºŠè©¦é©—æˆ–æ–‡ç»**æ”¯æŒé€™äº›æ–°é©æ‡‰ç—‡ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è§£ç†±ã€é®ç—›ã€é—œç¯€ç‚ã€ç¥ç¶“ç—› |
| é æ¸¬æ–°é©æ‡‰ç—‡ | osteoarthritis susceptibilityã€osteoarthritisã€rheumatoid arthritisã€acromesomelic dysplasia, Hunter-Thompson typeã€brachyolmia-amelogenesis imperfecta syndromeã€myosclerosisã€brachyolmia |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.74% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | æœ‰æ•ˆè¨±å¯è­‰ |
| è¨±å¯è­‰æ•¸ | 435 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. acromesomelic dysplasia, Hunter-Thompson type</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.74%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Ibuprofen æ˜¯ä¸€ç¨®éé¡å›ºé†‡æ¶ˆç‚è—¥ï¼ˆNSAIDï¼‰ï¼Œé€éæŠ‘åˆ¶ç’°æ°§åˆé…¶ï¼ˆCOXï¼‰é™ä½å‰åˆ—è…ºç´ åˆæˆï¼Œ
é”åˆ°è§£ç†±ã€é®ç—›å’Œæ¶ˆç‚çš„æ•ˆæœã€‚

**é æ¸¬åˆ†æï¼š**
TxGNN é æ¸¬çš„é©æ‡‰ç—‡åŒ…æ‹¬å¤šç¨®ç½•è¦‹éª¨éª¼ç™¼è‚²ç•°å¸¸ç–¾ç—…ï¼š
- è‚¢ç«¯è‚¢ä¸­ç™¼è‚²ä¸è‰¯ Hunter-Thompson å‹
- çŸ­è»€é«”é‡‰è³ªç™¼è‚²ä¸å…¨ç—‡å€™ç¾¤
- è‚Œç¡¬åŒ–ç—‡
- çŸ­è»€é«”ç—‡
- çŸ­æŒ‡ä½µæŒ‡ç—‡å€™ç¾¤
- å‡æ€§è»Ÿéª¨ç™¼è‚²ä¸å…¨
- çœ¼ç¼ºæå°çœ¼ç•¸å½¢-è¿‘å´è‚¢çŸ­ç•¸å½¢ç—‡å€™ç¾¤

**æ©Ÿè½‰è€ƒé‡ï¼š**
- é€™äº›ç½•è¦‹ç–¾ç—…ä¸»è¦æ˜¯éºå‚³æ€§éª¨éª¼ç™¼è‚²ç•°å¸¸
- Ibuprofen çš„ COX æŠ‘åˆ¶æ©Ÿè½‰èˆ‡éª¨éª¼ç™¼è‚²ç„¡ç›´æ¥é—œè¯
- é æ¸¬å¯èƒ½åæ˜  ibuprofen åœ¨éª¨éª¼ç›¸é—œç–¼ç—›ç®¡ç†ä¸­çš„å»£æ³›ä½¿ç”¨
- ä½†ç„¡æ³•æ²»ç™‚ç–¾ç—…æœ¬èº«ï¼Œåƒ…èƒ½ç·©è§£ç—‡ç‹€

### è‡¨åºŠè©¦é©—

ç›®å‰**ç„¡è‡¨åºŠè©¦é©—**ç ”ç©¶ ibuprofen ç”¨æ–¼ä»»ä½•é æ¸¬çš„éª¨éª¼ç™¼è‚²ç•°å¸¸ç–¾ç—…ã€‚

### ç›¸é—œæ–‡ç»

ç›®å‰**ç„¡ PubMed æ–‡ç»**ç›´æ¥æ¢è¨ ibuprofen ç”¨æ–¼é€™äº›ç½•è¦‹ç–¾ç—…çš„æ²»ç™‚ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. brachyolmia-amelogenesis imperfecta syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.71%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. myosclerosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.68%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.68%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. brachyolmia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.67%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. brachydactyly-syndactyly syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.66%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.66%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. pseudoachondroplasia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.66%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.66%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. colobomatous microphthalmia-rhizomelic dysplasia syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.60%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.60%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028707è™Ÿ | æ„›å©å’è†œè¡£éŒ 400æ¯«å…‹ | è†œè¡£éŒ  | è§£ç†±ã€æ¶ˆç‚ã€é®ç—› |
| è¡›éƒ¨è—¥è£½å­—ç¬¬058382è™Ÿ | å¸ƒæ´›èŠ¬æ³¨å°„æ¶²100æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | é®ç—›ã€é€€ç‡’ï¼ˆæˆäººåŠ6å€‹æœˆä»¥ä¸Šå…’ç«¥ï¼‰ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬061021è™Ÿ | ç›Šç™¾ç†±é æ··åˆæ³¨å°„æ¶² | æ³¨å°„æ¶²åŠ‘ | é®ç—›ã€é€€ç‡’ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬061099è™Ÿ | ç†å†’ä¼Šæ™®è†œè¡£éŒ 400æ¯«å…‹ | è†œè¡£éŒ  | è§£ç†±ã€æ¶ˆç‚ã€é®ç—› |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027985è™Ÿ | é€Ÿæ²»ç–¼è»Ÿè† å›Š400æ¯«å…‹ | è»Ÿè† å›ŠåŠ‘ | é ­ç—›ã€è‚Œè‚‰ç–¼ç—›ã€ç‰™ç—›ã€ç¶“ç—›ã€è§£ç†± |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼ˆä¾†è‡ª DDI è³‡æ–™åº«ï¼‰ï¼š
  - **Major**ï¼šAcetylsalicylic acidï¼ˆé˜¿æ–¯åŒ¹éˆï¼‰- å¢åŠ èƒƒè…¸å‡ºè¡€é¢¨éšª
  - **Moderate**ï¼šMetforminã€é¡å›ºé†‡ã€ç£ºè„²é¡é™è¡€ç³–è—¥ã€é‰€é¹½è£½åŠ‘ã€å–¹è«¾é…®é¡æŠ—ç”Ÿç´ 
  - **Minor**ï¼šH2 å—é«”æ‹®æŠ—åŠ‘ã€Linaclotide
- **NSAID é¡è­¦èª**ï¼š
  - å¢åŠ å¿ƒè¡€ç®¡äº‹ä»¶é¢¨éšªï¼ˆå¿ƒè‚Œæ¢—å¡ã€ä¸­é¢¨ï¼‰
  - èƒƒè…¸é“å‡ºè¡€å’Œæ½°ç˜é¢¨éšª
  - è…åŠŸèƒ½å—ææ‚£è€…éœ€è¬¹æ…ä½¿ç”¨
  - é¿å…æ–¼å† ç‹€å‹•è„ˆç¹é“æ‰‹è¡“å‰å¾Œä½¿ç”¨

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šThe concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as...
- å»ºè­°ï¼šPatients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Phenylketonurias** ğŸŸ¡ Moderate
- Chewable products frequently may contain aspartame, which is metabolized in the gastrointestinal tract to phenylalanine.  Motrin (brand of ibuprofen) chewable 50 mg and 100 mg tablets provide the equivalent of 3 mg and 6 mg of phenylalanine each, res...

**Anemia** ğŸŸ¡ Moderate
- Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be ...

**å¿ƒè‡Ÿè¡°ç«­ (Heart Failure)** ğŸŸ¡ Moderate
- Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are exp...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevati...

**Hyperkalemia** ğŸŸ¡ Moderate
- Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects h...

*å¦æœ‰ 8 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
- é æ¸¬çš„é©æ‡‰ç—‡å‡ç‚ºéºå‚³æ€§éª¨éª¼ç™¼è‚²ç•°å¸¸ï¼Œibuprofen çš„æ©Ÿè½‰ç„¡æ³•é‡å°é€™äº›ç–¾ç—…çš„æ ¹æœ¬ç—…å› 
- å®Œå…¨ç¼ºä¹æ”¯æŒæ€§çš„è‡¨åºŠæˆ–æ–‡ç»è­‰æ“š
- é æ¸¬å¯èƒ½æ˜¯çŸ¥è­˜åœ–è­œä¸­ã€Œéª¨éª¼ç›¸é—œç–¼ç—›ã€é—œè¯çš„éåº¦æ³›åŒ–
- é€™äº›ç½•è¦‹ç–¾ç—…ç›®å‰ç„¡å·²çŸ¥è—¥ç‰©æ²»ç™‚ï¼Œéœ€è¦åŸºå› æ²»ç™‚æˆ–å…¶ä»–å‰µæ–°ç™‚æ³•

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ¾„æ¸… TxGNN é æ¸¬çš„æ©Ÿè½‰åŸºç¤
- è‹¥ç›®çš„æ˜¯ç—‡ç‹€ç·©è§£ï¼ˆç–¼ç—›ç®¡ç†ï¼‰ï¼Œéœ€æ˜ç¢ºæ­¤è§’è‰²å®šä½
- é€™äº›é©æ‡‰ç—‡ä¸é©åˆä½œç‚ºè€è—¥æ–°ç”¨çš„é–‹ç™¼æ–¹å‘


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Tizanidine]({{ "/drugs/tizanidine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Nebivolol]({{ "/drugs/nebivolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Timepidium]({{ "/drugs/timepidium/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Belimumab]({{ "/drugs/belimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ibuprofenè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ibuprofen/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ibuprofen,
  title = {Ibuprofenè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ibuprofen/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
